This is a company that certainly provides a very needed process, finding side effect that sometimes end up being another form of treatment or therapy for existing drugs. The company uses a software platform for some very extensive research. The company started working with the FDA in predicting adverse effects and has evolved into a company that repositions drugs.
They study compounds and find correlations by looking through pub med data. They take a drug that already has FDA approval and find a beneficial side effect that in many instances becomes a drug that could be prescribed for another therapy.
Pfizer and Novartis are a couple of their current clients. You can visit the website and find out more about some of their current projects and processes.
Micro-Cap Review Latest Issue
Cavaet Emptor or Buyer Beware by SNN Inc. CEO Sheldon “Shelly” Kraft
Check out the book "Caveat Emptor" written by CEO Sheldon Kraft, click on the image to view a preview and the full book can be purchased for $15.95.
There are some best practices and good hints on what to look out for in today’s volatile markets.